Neurocrine Biosciences

Neurology and Endocrinology Research and Therapy | Neurocrine Biosciences.

Launch date

1992

Employees

1001-5000 people

Market cap

Enterprise valuation

€10.4b (Public information from Sep 2024)

San Diego California (HQ)

http://neurocrine.com

https://www.linkedin.com/company/neurocrine-biosciences https://apps.apple.com/app/id1436212271 https://play.google.com/store/apps/details?id=mobile.appOdX1QFG68D

View job openings

Revenues, earnings & profits over time

USD	2020	2021	2022	2023	2024	2025	2026
Revenues	1.0b	1.1b	1.5b	1.9b	2.3b	2.7b	3.2b
% growth	33 %	8 %	31 %	27 %	24 %	16 %	18 %
EBITDA	328m	208m	249m	416m	630m	849m	1.2b
% EBITDA margin	31 %	18 %	17 %	22 %	27 %	31 %	37 %
Profit	407m	89.6m	155m	250m	455m	706m	967m
% profit margin	39 %	8 %	10 %	13 %	19 %	26 %	30 %
EV / revenue	8.1x	6.8x	7.0x	6.0x	4.7x	3.7x	2.9x
EV / EBITDA	25.9x	37.1x	41.6x	27.4x	17.3x	11.9x	7.8x
R&D budget	275m	328m	464m	565m	-	-	-
R&D % of revenue	26 %	29 %	31 %	30 %	-	-	-

Source: Dealroom estimates

Date	Investors	Amount	Round
-	International Biotechnology Trust	N/A	-
May 1996	N/A	N/A	IPO
Dec 2009	Venrock	$10.0m	Post IPO Equity
Total Funding		-

Tech stackLearn more about the technologies and tools that this company uses.

Voyager Therapeutics

exited

ACQUISITION by Neurocrine Biosciences Aug 2022

Xenon Pharmaceuticals

exited